DUSA Pharmaceuticals, Inc.
24
0
0
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
2 terminated/withdrawn out of 24 trials
90.9%
+4.4% vs industry average
21%
5 trials in Phase 3/4
60%
12 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Role: collaborator
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Role: collaborator
Photodynamic Therapy for Papulopustular Rosacea
Role: collaborator
Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis
Role: collaborator
Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients
Role: collaborator
Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
Role: collaborator
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
Role: collaborator
Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Role: collaborator
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
Role: lead
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
Role: lead
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
Role: lead
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
Role: lead
A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy
Role: collaborator
Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ
Role: collaborator
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
Role: lead
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
Role: lead
Twelve Month Follow-Up of CP0108
Role: lead
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Role: lead
A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Role: collaborator
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
Role: lead